Zollinger-Ellison syndrome screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Zollinger-Ellison syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Zollinger-Ellison syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Zollinger-Ellison syndrome screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Zollinger-Ellison syndrome screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Zollinger-Ellison syndrome screening
CDC on Zollinger-Ellison syndrome screening
Zollinger-Ellison syndrome screening in the news
Blogs on Zollinger-Ellison syndrome screening
Directions to Hospitals Treating Zollinger-Ellison syndrome
Risk calculators and risk factors for Zollinger-Ellison syndrome screening

Overview

There is insufficient evidence to recommend routine screening for Zollinger-Ellison syndrome.

Screening

• The single best screening test for Zollinger-Ellison syndrome (ZES) is by measuring fasting serum gastrin levels.
• At the time of the test, it is advised not to take gastric antisecretory medications.
• Serial multiple measurements on different days have to be performed because, fasting gastrin levels can fluctuate from day to day and can appear to be normal.
• Normal levels of serum gastrin in untreated ZES are extremely rare (<1%)
• Multiple endocrine neoplasia-type 1 (MEN 1) syndrome should be suspected if serum calcium levels are elevated.